

OTCQB Certification

I, Darlene Deptula-Hicks, Acting Chief Financial Officer of Pieris Pharmaceuticals, Inc. ("the Company"), certify that:

a. The Company is registered with the SEC or exempt from SEC registration as indicated below (check one):

- Company is registered under Section 12g of the Exchange Act
- Company is relying on Exchange Act Rule 12g3-2(b)
- Company is a bank that reports to a Bank Regulator under Section 12(i) of the Exchange Act
- Company is a bank that is non-SEC reporting but is current in its reporting to a Banking Regulator
- Other (describe) Voluntary Filer under Section 15(d)

b. The Company is current in its reporting obligations as of the most recent fiscal year end and any subsequent quarters, and such information has been posted either on the SEC's EDGAR system or the OTC Disclosure & News Service, as applicable.

c. The Company Profile displayed on www.otcmarkets.com is current and complete as of March 13, 2015 and includes the total shares outstanding, authorized, and in the public float as of that date.

d. The following is a complete list of attorney(s) and law firm(s) who advised or assisted in the preparation of the Company's most recent annual report, including in-house counsel: (If no attorney assisted in putting together the disclosure, indicate the person or persons who prepared the disclosure and their relationship to the company.)

FY2013

Aleksandrs Sviks

Murjanu sit. 54-35

Riga, Latvia LV-1064

No attorneys assisted in the FY2013 10K; Mr. Sviks is a former director, former shareholder and former president.

FY2014 (to be filed by 3/31/15)

Marc D. Mantel, Esq.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

One Financial Center

Boston, MA 02111

Jiang Bian, Esq.

Pieris Pharmaceuticals, Inc.

Lise-Meitner-Strasse 30

85354 Freising-Weihenstephan, Germany

e. The following is a complete list of third party providers, including names and addresses, engaged by the Company, its officers, directors or controlling shareholders, during the period from the Company's prior fiscal year end to the date of this OTCQB Certification, to provide investor relations services, public relations services, or other related services to the Company including promotion of the Company or its securities:

The Trout Group

Thomas Hoffman, Sr. VP

740 Broadway, 9th Floor

New York, NY 10003

DelMar Consulting Group, Inc.

Robert Prag, President

2455 El Amigo Road

DelMar, CA 92014

MacDougall Biomedical Communications

OTC Markets

888 Worcester St.
Wellesley, MA 02482

Alex Partners, LLC
Scott Wilfong, President
6427 Lake Washington Blvd. NE
Kirkland, WA 98033

f. Listed below are the names, legal addresses and % of shares owned by all Officers, Directors and Control Persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities). If any of the beneficial shareholders are corporate shareholders, the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders must also be included.


Name	Address (City and State only)	% Shares Owned
The Global Life Science Ventures Fund II GmbH & Co. KG Dr. Hans A. Kupper, Hanns-Peter Wiese, Barry McClay, Martijn Hes and Peter Touzeau	Tal 26, 80321 Munchen, Germany	4.77%
The Global Life Science Ventures Funds II Limited Partnership Dr. Hans A. Kupper, Hanns-Peter Wiese, Barry McClay, Martijn Hes and Peter Touzeau	, 1 Royal Plaza, Royal Avenue, St. Peter Port, Guernsey, United Kingdom	3.71%
Novo Nordisk A/S Board of Directors comprised of 11 Directors	Novo Alle, Bagsvaerd, 2880, Denmark	7.01%
Gilde Europe Food & Agribusiness Fund B.V. Marc Oliver Perret, Edwin de Graaf and Pieter van der Meer	Newtonlaan 91, Utrecht, 3508 AB, Netherlands	8.31%
Orbimed Associates III, LP Samuel D. Isaly	601 Lexington Avenue, 54 th Floor New York, NY 10022	0.21%
Orbimed Private Investments III, LP Samuel D. Isaly	601 Lexington Avenue, 54 th Floor New York, NY 10022	22.88%
1798 Fundamental Strategies Master Fund Ltd. Lombard Odier Asset Management (USA) Corp., a Delaware corporation is the investment adviser to the 1798 Funds and as such has voting and dispositive power over the ordinary shares	888 Seventh Ave., 11 th Floor, New York, NY 10106	5.12%
Tompkins, Mark N.	App. 1, Via Guidino 23, 6900 Lugano-Paradis0, Switzerland	8.20%

OTC Markets

Date: March 20, 2015

Name of Certifying CEO or CFO: Darlene Deptula-Hicks

Title: Acting Chief Financial Officer

Signature: 
(Digital Signatures should appear as "/s/ [OFFICER NAME]")